HIV-1复制能力与疾病替代标志物之间的相互作用
研究采用新型高通量原代细胞感染试验,测定急性期和近期原发HIV-1感染(PHI)样本中355株全基因组原发HIV-1分离株的复制能力(RC),分析RC与病毒学及免疫学指标的关系;结果显示较高的RC与较高的设定点病毒载量(VL)相关,13种HIV-1亚型间RC存在显著差异,B亚型分离株的RC在17年间呈升高趋势;RC与CD4计数、CD4恢复、CD4下降及急性逆转录病毒综合征严重程度评分均无关联。
要点
- 较高的RC与较高的设定点VL相关,RC更多与病毒因素而非宿主因素相关。
- 13种HIV-1亚型间RC存在显著差异,B亚型RC在17年间呈升高趋势。
- RC与CD4计数、CD4恢复、CD4下降及急性逆转录病毒综合征严重程度评分无关联。
核心结论
- 急性期和近期PHI阶段获得的原发HIV-1分离株的RC更多与病毒因素(即设定点VL)相关,而非与宿主因素相关。
- 研究观察到HIV-1 B亚型病毒的RC在17年间呈时间性升高。
研究设计与样本
- 研究为实验室分析,采用新型高通量原代细胞感染试验测定355株全基因组原发HIV-1分离株的RC。
- 分离株来源于急性期和近期原发HIV-1感染(PHI)期间采集的样本。
- 临床试验注册号:NCT00537966。
主要发现
- RC升高与设定点病毒载量(VL)升高相关。
- 13种不同HIV-1亚型间RC存在显著差异。
- HIV-1 B亚型的原发分离株RC在17年间呈升高。
- RC与RC测量采样日的CD4计数、启动抗逆转录病毒治疗后的CD4恢复、未治疗个体的CD4下降及急性逆转录病毒综合征严重程度评分之间均未观察到关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-1 replication capacity (RC) of transmitted/founder viruses may influence the further course of HIV-1 infection. METHODS: RCs of 355 whole-genome primary HIV-1 isolates derived from samples acquired during acute and recent primary HIV-1 infection (PHI) were determined using a novel high-throughput infection assay in primary cells. The RCs were used to elucidate potential factors that could be associated with RC during PHI. RESULTS: Increased RC was found to be associated with increased set point viral load (VL), and significant differences in RCs among 13 different HIV-1 subtypes were discerned. Notably, we observed an increase in RCs for primary HIV-1 isolates of HIV-1 subtype B over a 17-year period. Associations were not observed between RC and CD4 count at sample date of RC measurement, CD4 recovery after initiation of antiretroviral treatment, CD4 decline in untreated individuals, and acute retroviral syndrome severity scores. CONCLUSIONS: These findings highlight that RCs of primary HIV-1 isolates acquired during the acute and recent phase of infection are more associated with viral factors, that is set point VL, than with host factors. Furthermore, we observed a temporal increase in RC for HIV-1 subtype B viruses over a period of 17 years. CLINICAL TRIALS REGISTRATION: NCT00537966.
引用
- Rindler AE, Kusejko K, Kuster H, et al. The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. J Infect Dis. 2022. PMID: 35299248. doi:10.1093/infdis/jiac100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。